QuickMD adds a pay-per-visit menopause service to the ledger. Its advertised clinical fee is $79, with no subscription required, while medication has its own price. That structure is straightforward to record but still needs to be matched to the care you expect to use.
This entry checks QuickMD's official treatment page, program guidance and FAQ as of September 21, 2026. We did not enroll or receive care. Published prices and service descriptions are evidence of the advertised offering, not independent proof of treatment quality or guaranteed eligibility.
In this entry
Record the clinical fee first
QuickMD describes a live appointment by video or phone. Its MHT guidance says each visit costs $79, payable when booking, and describes initial assessment followed by further appointments as needed. The fee does not include all future care simply because the first visit starts an ongoing treatment plan.
Ask when the clinician expects to see you again and which questions require another appointment. If you currently take HRT, clarify what records are needed before the new clinician can decide whether to continue it. Our care-transfer guide helps organize the handoff without assuming an automatic refill.
Record medication on another line
The menopause page lists home-delivery starting prices for 30-day supplies: $24 for estradiol tablets, $29 for progesterone capsules and $64 for estradiol patches. These are separate product entries. They should not be added into a standard package unless that is the actual regimen prescribed.
The lower-priced estrogen product is not necessarily an appropriate substitute for another route. Ask what each proposed medicine is for and which costs are recurring. In the cost worksheet, enter the verified medication quote separately from appointments so a modest visit fee does not hide the ongoing expense.
The insurance limitation is explicit
QuickMD's general FAQ says insurance is not accepted at this time. It describes documentation a patient may submit to private insurance for possible reimbursement. That possibility does not convert the visit into in-network care or guarantee a refund from an insurer.
If reimbursement matters to your decision, obtain the necessary billing details and ask your plan about its requirements before relying on it. Prescription coverage is a separate question. Confirm whether the intended medication can be filled through your preferred pharmacy and benefit; the published delivery price alone cannot answer that.
Delivery speed begins with a filled order
QuickMD advertises free two-day shipping for medication orders. The article does not treat that as a guarantee that a new patient will be assessed, prescribed, dispensed and supplied within two days. Those steps have different dependencies, including the clinician's decision and the product's availability.
Ask when the pharmacy expects to dispatch your particular order, who provides tracking and how a delay is handled. Keep the storage and use instructions attached to the dispensed product. The delivery shortlist compares how different programs divide the responsibilities of clinical care and fulfillment.
Check access for the exact service
QuickMD points patients to availability information, and not every company service should be assumed available in every location. Confirm menopause care in the state where you will physically receive the appointment. A listing for urgent care or another QuickMD program does not resolve that question.
Ask whether the visit will be by phone or video and what information must be ready beforehand. The program guidance discusses reviewing medical history and any relevant lab information. This is not evidence that every person needs the same testing. Bring existing records and let the clinician explain any additional assessment required.
The medicine needs its own review
Identify the prescribed ingredient, route, intended symptom and approval status. Menopause catalogs can contain different kinds of products; a brand name does not tell you whether every preparation is FDA-approved. If compounding is proposed, ask the reason and the available approved alternatives.
Our approved-versus-compounded guide explains the regulatory distinction. The estradiol guide explains why local vaginal treatment and systemic estrogen are not interchangeable. The complete regimen also needs to address uterine protection when indicated, rather than selecting medicine from a price list alone.
Decide whether per-visit care fits
The model may appeal to an eligible person who wants each appointment priced separately and can budget for prescriptions. Someone expecting direct insurance billing should account for the stated restriction. Someone expecting unlimited between-visit access should ask for the actual communication terms instead of assuming them.
Read QuickMD versus Midi to compare the opening and follow-up costs with another visit-based service. Use the same expected period of care and keep medication separate. Our review supports those practical comparisons; it does not establish that the least expensive visit is the best clinical choice.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. Latest source check: September 21, 2026.